Ravindra Kumar Net Worth

The estimated Net Worth of Ravindra Kumar is at least $23.1 million dollars as of 10 September 2019. Ravindra Kumar owns over 3,389 units of Acceleron Pharma Inc stock worth over $15,548,748 and over the last 11 years he sold XLRN stock worth over $6,355,343. In addition, he makes $1,210,840 as Senior Vice President et Chief Scientific Officer at Acceleron Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ravindra Kumar XLRN stock SEC Form 4 insiders trading

Ravindra has made over 32 trades of the Acceleron Pharma Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 3,389 units of XLRN stock worth $153,318 on 10 September 2019.

The largest trade he's ever made was selling 52,486 units of Acceleron Pharma Inc stock on 6 October 2016 worth over $1,780,325. On average, Ravindra trades about 6,790 units every 49 days since 2013. As of 10 September 2019 he still owns at least 86,986 units of Acceleron Pharma Inc stock.

You can see the complete history of Ravindra Kumar stock trades at the bottom of the page.

Ravindra Kumar biography

Dr. Ravindra Kumar Ph.D serves as Senior Vice President, Chief Scientific Officer of the Company. He is Senior Vice President, Chief Scientific Officer of Acceleron Pharma, Inc. Dr. Kumar established and currently leads our discovery research. Previously, Dr. Kumar worked for 12 years at Genetics Institute and Wyeth Pharmaceuticals. At Genetics Institute, Dr. Kumar was a key member of the Small Molecule Drug Discovery group and was responsible for cell biology. Following the integration of discovery functions from Genetics Institute and Wyeth Pharmaceuticals, Dr. Kumar served as Senior Scientist in the Biological Chemistry group. Dr. Kumar is the author of several key scientific manuscripts in the area of protein glycosylation and is named as an inventor of several patents. Dr. Kumar received his BS in chemistry from Rohilkhand University, his M S in chemistry from Meerut University, his Ph.D. from University of New Brunswick and he completed his post-doctoral fellowship at Albert Einstein College of Medicine, in Bronx, NY.

What is the salary of Ravindra Kumar?

As the Senior Vice President et Chief Scientific Officer of Acceleron Pharma Inc, the total compensation of Ravindra Kumar at Acceleron Pharma Inc is $1,210,840. There are 3 executives at Acceleron Pharma Inc getting paid more, with Habib Dable having the highest compensation of $4,273,090.

How old is Ravindra Kumar?

Ravindra Kumar is 59, he's been the Senior Vice President et Chief Scientific Officer of Acceleron Pharma Inc since 2016. There are 5 older and 6 younger executives at Acceleron Pharma Inc. The oldest executive at Acceleron Pharma Inc is Jay Backstrom, 65, who is the Executive Vice President - Research and Development.

Insiders trading at Acceleron Pharma Inc

Over the last 11 years, insiders at Acceleron Pharma Inc have traded over $211,038,855 worth of Acceleron Pharma Inc stock and bought 4,435,573 units worth $172,392,007 . The most active insiders traders include Corp /De/ Celgene, Richard F Pops et Anthony B Evnin. On average, Acceleron Pharma Inc executives and independent directors trade stock every 10 days with the average trade being worth of $7,646,210. The most recent stock trade was executed by Adam M Veness on 9 November 2021, trading 4,500 units of XLRN stock currently worth $132,165.

What does Acceleron Pharma Inc do?

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Complete history of Ravindra Kumar stock trades at Acceleron Pharma Inc

Acceleron Pharma Inc executives and stock owners

Acceleron Pharma Inc executives and other stock owners filed with the SEC include:

• Habib Dable,
  President, Chief Executive Officer, Director
• Kevin McLaughlin,
  Chief Financial Officer, Senior Vice President, Treasurer
• Sujay Kango,
  Executive Vice President and Chief Commercial Officer
• Ravindra Kumar,
  Senior Vice President, Chief Scientific Officer
• Francois Nader,
  Independent Chairman of the Board
• Joseph Zakrzewski,
  Independent Director
• Terrence Kearney,
  Independent Director
• Thomas McCourt,
  Independent Director
• Karen Smith,
  Independent Director
• Todd James,
  Senior Vice President Corporate Affairs and Investor Relations
• Kemal Malik,
  Independent Director
• Christopher Hite,
  Director
• Laura Hamill,
  Director
• Jay Backstrom,
  Executive Vice President - Research and Development
• Terrance Mcguire,
  Director
• Tom Maniatis,
  Director
• Jean George,
  Director
• John L Knopf,
  CEO and President
• Steven D Ertel,
  SVP & Chief Business Officer
• Matthew L Sherman,
  SVP & Chief Medical Officer
• Richard F Pops,
  Director
• Adam M Veness,
  SVP, General Counsel and Sec.
• John D Quisel,
  EVP, Chief Business Officer
• Christopher Rovaldi,
  SVP, Program Mgmt and Ops
• Robert K Zeldin,
  EVP & Chief Medical Officer
• Corp /De/ Celgene,
  10% owner
• Anthony B Evnin,
  Director
• Edwin M Jr Kania,
  Director
• Venture Management Co Iv Ll...,
  
• Venture Management Co Iv Ll...,
  
• Advisors Llcorbimed Capital...,
  
• Corp /De/Bristol Myers Squi...,